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Survival analysisAbstract Background: In the phase 3 randomised NAPOLI-1 clinical study, a 45% increase
in median overall survival (OS) was shown with liposomal irinotecan, 5-fluorouracil and leu-
covorin (nal-IRIþ5-FU/LV) versus 5-FU/LV in patients with metastatic pancreatic cancer
progressing after gemcitabine-based therapy. Here, we report data from a pre-specified,
expanded analysis of outcomes in the per-protocol (PP) population.
Materials and methods: The PP population comprised patients receiving 80% of planned
treatment during the first 6 weeks, with no major protocol violations. A post-hoc analysis
of the non-PP population was also performed.
Results: For PP patients, median OS was 8.9 (95% confidence interval: 6.4e10.5) months with
nal-IRIþ5-FU/LV (nZ 66) vs 5.1 (4.0e7.2) months with 5-FU/LV (nZ 71; unstratified haz-
ard ratio [HR] 0.57, p Z 0.011). For non-PP patients, it was 4.4 (3.3e5.3) months with
nal-IRIþ5-FU/LV (n Z 51) vs 2.8 (1.7e3.2) months with 5-FU/LV (n Z 48; unstratified
HR 0.64, p Z 0.0648).
Conclusion: A statistically significant survival advantage was observed with nal-IRIþ5-FU/LV
vs 5-FU/LV in the PP patient population.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic cancer has a poor prognosis, with recently
reported estimated median overall survival (OS) of 4.6
months [1]. Gemcitabine plus nab-paclitaxel and the
FOLFIRINOX (5-fluorouracil/leucovorin [5-FU/LV]þ
irinotecan þ oxaliplatin) regimen are recommended for
the first-line treatment of metastatic pancreatic ductal
adenocarcinoma in patients with good performance sta-
tus, whereas gemcitabine monotherapy and other
gemcitabine-based combinations may be used in less fit
patients [2e5]. Combination therapy with liposomal iri-
notecan (nal-IRI) and 5-FU/LV is the first regimen
approved in the United States, the European Union,
Australia and Taiwan for the treatment of patients pro-
gressing after gemcitabine-based therapy, based on the
positive findings of the phase 3 NAPOLI-1 study
(NCT01494506) [6]. Liposomal irinotecan comprises iri-
notecan sucrosofate salt encapsulated in pegylated lipo-
somes that protect the drug frompremature conversion in
the liver into its 1000 times more active metabolite, SN-
38. This leads to extended circulation in plasma in pa-
tients and prolonged tumour exposure in pre-clinicaltumour models compared with non-liposomal irinote-
can [7e9]. It is proposed that locally enhanced perme-
ability of tissues at tumour sites promotes retention of
circulating liposomes and subsequent uptake and acti-
vation by tumour-associated macrophages, resulting in
sustained high local concentrations of SN-38 [8,10e12].
In NAPOLI-1, median OS was significantly extended
in patients receiving nal-IRIþ5-FU/LV (median 6.1
months; 95% confidence interval [CI]: 4.8e8.9) compared
with controls receiving 5-FU/LV only (4.2 months; 95%
CI: 3.3e5.3) (unstratified hazard ratio [HR] 0.67; 95%CI:
0.49e0.92; pZ 0.012), and this benefit was confirmed in
an updated survival analysis [13]. A recently published
analysis of the NAPOLI-1 data suggested that nal-
IRIþ5-FU/LV increased quality-adjusted survival vs 5-
FU/LV, with patients receiving this regimen having a
1.3-months longer mean quality-adjusted time without
symptoms of disease progression or grade3 toxicity (5.1
months; 95% CI: 4.5e5.8) compared with the 5-FU/LV
group (3.9 months; 95% CI: 3.3e4.5) [14].
The NAPOLI-1 data are encouraging as they demon-
strate efficacy in patients with advanced pancreatic cancer
who have progressed following gemcitabine-based
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in context due to significant differences in prior
treatment, patient characteristics, and outcome measures
among recent studies in this setting [15]. The NAPOLI-1
trial results have been included by recent treatment
guidelines, such that the nal-IRIþ5-FU/LV combination
is now recommended for these patients [3,5,16e18].
Here, we report the findings of a pre-specified expanded
analysis on the survival outcomes in the NAPOLI-1 per-
protocol (PP) population as a sensitivity analysis to
confirm that the efficacy of the nal-IRIþ5-FU/LV regimen
seen in the ITT population was also seen in PP patients
receiving optimal or near-optimal scheduled treatment.
We additionally discuss data from an unplanned analysis
of the non-PP population (including patients not receiving
planned treatment, e.g. due to toxicity or clinical
deterioration).
2. Methods
The study design and methodology for NAPOLI-1 have
been published previously [6]. This three-arm study
assessed efficacy and tolerability of nal-IRI mono-
therapy (120 mg/m2 Q3 weeks [Q3W]), 5-FU/LV
(200 mg/m2 LV then 2000 mg/m2 5-FU, 24 h infusion
QW for the first 4 weeks of each 6-week cycle) and, after
safety data becoming available on this combination, nal-
IRIþ5-FU/LV (80 mg/m2 nal-IRI [irinotecan hydro-
chloride trihydrate salt; equivalent to 70 mg/m2 irino-
tecan free base], subsequently 400 mg/m2 LV, then
2400 mg/m2 5-FU, 46 h infusion Q2W) in adults with
metastatic pancreatic ductal adenocarcinoma who had
progressed after gemcitabine-based therapy. Patients
had a Karnofsky Performance Status (KPS) score 70
and adequate haematologic, hepatic and renal function.
This PP analysis used the same cut-off date as the
pivotal analysis; the analysis of non-PP population data
was not pre-planned. Data for nal-IRI monotherapy are
not included here as, although the survival data sug-
gested clinical activity in NAPOLI-1, OS was not
significantly increased vs 5-FU/LV.
The PP population was defined as patients who met
inclusion criteria, were treated as randomised, received
80% of protocol-defined treatment during the first 6
weeks with no more than one dose reduction in the nal-
IRI containing arms and did not receive any prohibited
treatments.
Treatment groups were compared for OS using an
unstratified log-rank test. Only patients enrolled in the
5-FU/LV arm after a study protocol amendment to
include a nal-IRIþ5-FU/LV arm were included in this
analysis. Hazard ratios were estimated by Cox regres-
sion. Progression-free survival (PFS) and time to treat-
ment failure (TTF) were compared using the log-rank
method, and objective response rate (ORR) by Fisher’s
exact test. p-values for statistical significance (defined ata level of p < 0.05) are presented for descriptive
purposes.
3. Results
Of 117 patients in the nal-IRIþ5-FU/LV group and 119
patients in the 5-FU/LV group who were randomised to
treatment, 66 and 71 patients in these groups (56.4% and
59.7%), respectively, met the criteria for PP analysis (see
Fig. S1 for additional details on study population
composition). The non-PP populations for the nal-
IRIþ5-FU/LV and 5-FU/LV groups thus comprised 51
(43.6%) and 48 (40.3%) patients, respectively. Among
the non-PP population, 35 (68.6%) patients in the nal-
IRIþ5-FU/LV group and 17 (35.4%) patients in the 5-
FU/LV group were treated for the first 6 weeks but
received <80% dose. Early progression, clinical deteri-
oration or death led to exclusion of 8 patients in each
treatment group (15.6% and 16.6%, respectively) from
the PP population. Other reasons for not meeting PP
population criteria included not receiving any study
drug (2 and 13 patients, respectively) and consent
withdrawal or other reasons (4 and 6 patients, respec-
tively). For 11 of the 13 patients in the 5-FU/LV group
who did not receive any study drug, ‘subject decision’
was the reason recorded for treatment termination.
Treatment groups were generally well balanced with
regards to patients’ baseline demographic and clinical
characteristics (Table 1), except for a higher proportion
of patients of Asian ethnicity and a lower proportion of
Caucasian patients in the nal-IRIþ5-FU/LV non-PP vs
PP population groups and a lower incidence of
pancreatic head tumours in the 5-FU/LV non-PP pop-
ulation. The number of PP patients whose prior anti-
cancer therapy included a gemcitabine combination
regimen was somewhat higher in the nal-IRIþ5-FU/LV
group (59.1%) compared with the 5-FU/LV group
(50.7%) (Table 1). Conversely, prior anticancer therapy
with gemcitabine alone was more common in the 5-FU/
LV group (40.9% vs 49.3%). In non-PP patients, prior
treatment with gemcitabine alone was more common in
the nal-IRIþ5-FU/LV arm (51.0%) compared with the
5-FU/LV arm (41.7%). This was reversed with a prior
gemcitabine combination (49.0% vs 58.3%). A similar
number of patients in the PP and non-PP populations
treated with 5-FU/LV had previously received anti-
cancer therapy containing irinotecan (10 [14.1%] and 7
[14.6%] patients, respectively) compared with those who
received nal-IRIþ5-FU/LV (6 [9.1%] and 6 [11.8%],
respectively). Non-PP patients in the 5-FU/LV group
more frequently received prior platinum-containing
therapy compared with those in the nal-IRIþ5-FULV
group (43.8% vs 33.3%). The proportion of PP patients
receiving post-study anticancer therapy was lower in
those treated with nal-IRIþ5-FU/LV (39.4%) compared
with 5-FU/LV (49.3%) and comparable among non-PP
Table 1
Baseline demographics and clinical characteristics of the PP and non-PP populations for the nal-IRIþ5-FU/LV and 5-FU/LV treatment groups.
nal-IRIþ5-FU/LV 5-FU/LV
PP (n Z 66) Non-PP (n Z 51) PP (n Z 71) Non-PP (n Z 48)
Median age, years (y) 63 64 62 62
Age <65 y, n (%) 36 (54.5) 27 (52.9) 45 (63.4) 32 (66.7)
Age 65 y, n (%) 30 (45.5) 24 (47.1) 26 (36.6) 16 (33.3)
Ethnicity, n (%)
Caucasian 47 (71) 28 (55) 45 (63) 30 (63)
East Asian 14 (21) 20 (39) 22 (31) 14 (29)
KPS, n (%)a
70e80 25 (37.9) 26 (51.0) 28 (39.4) 24 (50.0)
90 41 (62.1) 25 (49.0) 43 (60.6) 24 (50.0)
Albumin, n (%)a
<40 g/dl 34 (51.5) 30 (58.8) 37 (52.1) 28 (58.3)
40 g/dl 32 (48.5) 21 (41.2) 34 (47.9) 20 (41.7)
CA19e9, n (%)b
>40 U/ml 54 (81.8) 38 (79.2) 53 (75.7) 38 (86.4)
Other 12 (18.2) 10 (20.8) 17 (24.3) 6 (13.6)
Stage at diagnosis, n (%)
Stage 4 35 (53.0) 26 (51.0) 36 (50.7) 26 (54.2)
Other 31 (47.0) 25 (49.0) 35 (49.3) 22 (45.8)
Pancreatic tumour location, n (%)
Head 40 (60.6) 36 (70.6) 48 (67.6c) 21 (43.8c)
Other 26 (39.4) 15 (29.4) 23 (32.4) 27 (56.2)
Liver metastases, n (%)
Yes 42 (63.6) 33 (64.7) 53 (74.7) 31 (64.6)
No 24 (36.4) 18 (35.3) 18 (25.3) 17 (35.4)
Previous lines of metastatic therapy, n (%)
0 9 (13.6) 6 (11.8) 9 (12.7) 6 (12.5)
1 35 (53.0) 27 (52.9) 42 (59.2) 25 (52.1)
2 22 (33.3) 18 (35.3) 20 (28.2) 17 (35.4)
Prior anticancer therapy, n (%)d
Gemcitabine alone 27 (40.9) 26 (51.0) 35 (49.3) 20 (41.7)
Gemcitabine combination 39 (59.1) 25 (49.0) 36 (50.7) 28 (58.3)
Fluorouracil-containing 28 (42.4) 22 (43.1) 26 (36.6) 26 (54.2)
Irinotecan-containing 6 (9.1) 6 (11.8) 10 (14.1) 7 (14.6)
Platinum-containing 21 (31.8) 17 (33.3) 20 (28.2) 21 (43.8)
Post-study anticancer therapy, n (%)d 26 (39.4) 10 (19.6) 35 (49.3) 10 (20.8)
Gemcitabine combination 8 (12.1) 3 (5.9) 10 (14.1) 2 (4.2)
Fluorouracil-containing 18 (27.3) 4 (7.8) 25 (35.2) 5 (10.4)
Irinotecan-containing 5 (7.6) 3 (5.9) 7 (9.9) 2 (4.2)
Platinum-containing 15 (22.7) 4 (7.8) 17 (23.9) 5 (10.4)
Other non-investigational agents 8 (12.1) 5 (9.8) 9 (12.7) 0
Investigational agents 2 (3.0) 1 (2.0) 2 (2.8) 2 (4.2)
Not recorded 40 (60.6) 41 (80.4) 36 (50.7) 38 (79.2)
Median time since last therapy, months (1st and 3 rd quartiles) 1.4 (0.9, 2.1) 1.4 (1.0, 2.8) 1.2 (1.0, 2.3) 1.2 (1.0, 2.1)
Median time since diagnosis, months
(1st and 3rd quartiles)
10.3 (5.2, 15.8) 10.8 (6.6, 19.1) 10.3 (6.5, 15.1) 10.5 (5.6, 16.2)
Median time from last study drug exposure to first post-study anticancer
therapy, weeks (1st and 3rd quartiles)
3.14 (2.7, 5.9) 2.93 (2.4, 5.4) 3.14 (2.9, 4.9) 3.86 (1.4, 4.7)
KPS, Karnofsky Performance Status.
a KPS and albumin summaries are based on classification per randomisation.
b Includes only patients with a measured CA19-9 level prior to treatment.
c Significant (p < 0.01) difference between the PP and non-PP populations.
d Columns add up to 100% as some patients received more than one prior line of therapy or more than one post-study treatment anticancer
therapy and may therefore be included in more than one category.
L.-T. Chen et al. / European Journal of Cancer 105 (2018) 71e7874treatment groups (19.6% vs 20.8%) (Table 1). Few pa-
tients (<10% per arm) treated with nal-IRIþ5-FU/LV
or 5-FU/LV in the PP and non-PP populations received
post-study anticancer therapy containing non-liposomal
irinotecan.Among the PP population, median OS was 8.9 (95%
CI: 6.4e10.5) months with nal-IRIþ5-FU/LV vs 5.1
(4.0e7.2) months for the 5-FU/LV control (unstratified
HR 0.57, p Z 0.011) (Fig. 1A). For non-PP patients,
median OS was 4.4 (3.3e5.3) months with nal-IRIþ5-
Fig. 1. Overall survival for the PP* (A) and non-PP (B) patient populations. *Per-protocol (PP) population: eligible patients who met
inclusion criteria, were treated as randomised, received 80% of protocol-defined treatment during the first 6 weeks with no more than one
dose reduction in the nal-IRI containing arms and did not receive any prohibited treatments. Vertical bars indicate censoring points. CI,
confidence interval; HR, hazard ratio; mo, months.
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(unstratified HR 0.64, p Z 0.0648) (Fig. 1B). The
KaplaneMeier survival function estimates for the pro-
portion of PP population patients alive at 6 and 12
months, respectively, were 0.69 (95% CI: 0.56e0.79) and
0.34 (0.19e0.50) with nal-IRIþ5-FU/LV vs 0.43
(0.31e0.54) and 0.24 (0.12e0.37) with 5-FU/LV.
Median PFS (4.3 [95% CI: 3.1e5.7] vs 1.6 [1.4e2.6]
months, p < 0.0001), TTF (4.1 [2.8e5.4] vs 1.4 [1.4e2.4]
months, p Z 0.0001) and ORR (22.7% vs 1.4%,
p < 0.0001) were statistically significantly improved
among nal-IRIþ5-FU/LV- vs 5-FU/LV-treated PP
patients. Among non-PP patients, the median PFS with
nal-IRIþ5-FU/LV vs 5-FU/LV treatment was 1.6 (95%
CI: 1.4e2.8) vs 1.4 (1.2e1.7)months (not significant [NS]),
median TTF was 1.3 (1.1e1.5) vs 0.8 (0.6e1.2) months
(pZ 0.0221) and the ORR was 7.8% vs 0.0% (NS).
In the PP population, patients in the nal-IRIþ5-FU/
LV arm received a median of 7 cycles of randomised
treatment, compared with 2 cycles in the non-PP popu-
lation (Table 2). In the 5-FU/LV arm, themedian number
of cycles in the PP and non-PP populations was 1. PP
patients receiving nal-IRIþ5-FU/LV had increased time
on treatment for 6 (98.5%), 12 (62.1%) and 18
(54.5%) weeks compared with those receiving 5-FU/LV
(93.0%, 35.2% and 19.7%, respectively), in line with the
observed increased efficacy of nal-IRIþ5-FU/LV vs 5-
FU/LV (Table 2). The difference in time on treatment
was less pronounced in the non-PP population.
Table 2 shows grade 3 adverse events (AEs) with an
incidence5% in either population (PP or non-PP) of the
nal-IRIþ5-FU/LV group that had a 2% greater inci-
dence vs either population of the 5-FU/LV group,
whereas Table S1 shows all AEs with incidence 5% ineither treatment group. Themost common grade3 side-
effects with nal-IRIþ5-FU/LV were neutropenia, fatigue
and GI disturbances, in line with the primary analysis [6].
4. Discussion
The survival advantage with the nal-IRIþ5-FU/LV
combination vs 5-FU/LV originally reported for the ITT
population (median OS difference Z 1.9 months) was
more apparent in this pre-specified PP population anal-
ysis (difference Z 3.8 months). Differences between PP
and non-PP populations (e.g. a better KPS) and the
requirement for PP patients to receive 80% of planned
treatment in the first 6 weeks with no more than one
reduction in the nal-IRI containing arms, which excluded
most patients with rapid disease progression or early
death, explain that PP patients had a better prognosis. In
patients receiving nal-IRIþ5-FU/LV, median OS was 8.9
and 4.4 months (differenceZ 4.5 months) for the PP and
the non-PP population, respectively. In contrast, median
OS was 5.1 and 2.8 months (differenceZ 2.3 months) in
patients receiving 5-FU/LV for the respective PP and
non-PP populations. This analysis confirms the original
results, providing deeper understanding of the treatment
effect size estimate of the nal-IRIþ5-FU/LV combination
vs 5-FU/LV alone.
Other secondary outcomes such as PFS, TTF and
ORR also showed statistically significantly superior ef-
ficacy for the nal-IRIþ5-FU/LV regimen vs 5-FU/LV
among PP patients. In the PP population, a higher pro-
portion of post-study anticancer therapy was seen in the
5-FU/LV group, despite an increased survival with nal-
IRIþ5-FU/LV vs 5-FU/LV in these patients. While me-
dian OS was numerically larger with nal-IRIþ5-FU/LV
Table 2
Dose intensity and adverse events for the PP and non-PP populations of the nal-IRIþ5-FU/LV and 5-FU/LV treatment groups.a
nal-IRIþ5-FU/LV 5-FU/LV
PP (n Z 66) Non-PP (n Z 49) PP (n Z 71) Non-PP (n Z 35)
Number of cycles of randomised treatment receivedb
n 66 49 71 34
Mean (SD) 9.1 (6.67) 2.7 (2.32) 2.1 (2.02) 0.8 (0.83)
Median (1st and 3rd quartiles) 7.0 (3, 12) 2.0 (1, 3) 1.0 (1, 2) 1.0 (0, 1)
Minimum time on treatment, n (%)
6 weeks 65 (98.5)c 17 (33.3) 66 (93.0)c 11 (22.9)
12 weeks 41 (62.1) 6 (11.8) 25 (35.2) 6 (12.5)
18 weeks 36 (54.5) 4 (7.8) 14 (19.7) 3 (6.3)
Mean (SD) relative dose intensity, %d
nal-IRI 85.4 (15.8) 80.6 (19.9)e n/a 63.1 (n/a)f
5-FU/LV 86.4 (16.0) 81.2 (20.5)e 97.9 (6.0) 90.1 (17.5)e
Mean (SD) duration of exposure, weeks
nal-IRI 20.8 (14.6) 7.2 (7.4) n/a 26.1 (n/a)f
5-FU/LV 20.8 (14.6) 7.2 (7.4) 12.5 (11.9) 5.5 (6.1)
Patients with AEs resulting in, n (%)
Dose reduction 22 (33.3) 16 (32.7) 2 (2.8) 3 (8.6)
Dose delays 40 (60.6) 30 (61.2) 15 (21.1) 19 (54.3)
Treatment discontinuation 3 (4.5) 10 (20.4) 2 (2.8) 5 (14.3)
Grade ‡3 non-haematologic TEAEs occurring in ‡5% of patients in either population (PP or non-PP) of the nal-IRID5-FU/LV group with an incidence
‡2% greater than in either population of the 5-FU/LV group, %g
Abdominal pain 4.5 8.2 2.8 14.3
Asthenia 4.5 12.2 5.6 5.7
Biliary tract infection 0 6.1 1.4 0
Decreased appetite 1.5 8.2 1.4 2.9
Diarrhoea 12.1 12.2 7.0 5.7
Fatigue 13.6 14.3 5.6 0
Gastroenteritis 0 6.1 0 0
Nausea 9.1 6.1 1.4 2.9
Sepsis 0 8.2 0 2.9
Vomiting 7.6 16.3 2.8 2.9
Grade ‡3 haematologic TEAEs occurring in ‡5% of patients in either population (PP or non-PP) of the nal-IRID5-FU/LV group with an incidence
‡2% greater than in either population of the 5-FU/LV group, %g
Anaemia 7.6 12.2 5.6 2.9
Neutropeniah 22.7 32.7 2.8 5.7
White blood cell count decreased 3.0 14.3 0 0
Grade 5 AEs, %g
Patients with 1 AE leading to death (all causes) 0 2.01 5.62 14.33
AE, adverse event; CTCAE, common terminology criteria for adverse events; GI, gastrointestinal; n/a, not applicable; TEAE, treatment-emergent
adverse event.
Causes of death: 1 Septic shock, n Z 1; 2 Hepatic failure, pathological fracture, pulmonary oedema, septic shock, all n Z 1; 3 Hepatic failure,
hyperbilirubinaemia, jaundice, pneumonia, respiratory failure, tumour haemorrhage, upper GI haemorrhage, all nZ 1 with one patient having 3
events with fatal outcome. Only one death (a case of septic shock in a neutropenic patient in the nal-IRIþ5-FU/LV treatment group) was
considered to be possibly related to study treatment.
a Patients who did not receive any study drug are included in the non-PP population, but were neither included in the exposure summary nor in
the safety summary.
b Cycle lengths: 2 weeks for nal-IRIþ5-FU/LV and 6 weeks for 5-FU/LV.
c Values are <100% as patients who received their last scheduled dose earlier than the cut-off date of 6 weeks were categorised as <6 weeks on
treatment despite having received all required doses.
d Time from (date of the last administration of study drug þ projected days to the next dose e date of first administration)/7.
e Patients meeting the requirement to receive planned study treatment may have had other protocol violations requiring their classification into
the non-PP group.
f 1 patient randomised to the 5-FU/LV treatment group erroneously received 26 weeks of nal-IRI treatment (i.e. the nal-IRIþ5-FU/LV
combination).
g Per CTCAE, version 4.
h Includes neutropenia, neutrophil count decreased, febrile neutropenia, granulocytopenia, neutropenic sepsis, agranulocytosis and pancyto-
penia. Patients with more than one of these events are only counted once in the proportion estimate.
L.-T. Chen et al. / European Journal of Cancer 105 (2018) 71e7876vs 5-FU/LV in non-PP patients, this difference did not
reach statistical significance. Although the data for the
non-PP population do not demonstrate a statistically
significant survival advantage for the nal-IRIþ5-FU/LV
regimen, the HR of 0.64 and p-value of 0.0648 signal thatthe regimen can also benefit patients who experience
toxicities and require dose reductions.
Previous exploratory analyses of the NAPOLI-1 ITT
population data set have led to the development of an OS
nomogram for patients in this post-gemcitabine setting
L.-T. Chen et al. / European Journal of Cancer 105 (2018) 71e78 77[19]. The analysis, which also distinguished between risk
groups, identified the following predictors for OS: treat-
ment with nal-IRIþ5-FU/LV, KPS, neutrophil-to-
lymphocyte ratio, albumin level, baseline CA19-9, dis-
ease stage 4 at diagnosis, body mass index, and presence
of liver metastasis. While prediction of PP or non-PP
population assignment would be desirable in this treat-
ment setting, the OS nomogram methodology could not
be applied to the present analysis because of the limited
number of patients in both populations.
AEs reported with nal-IRIþ5-FU/LV treatment
(Table 2) were in line with previous observations in pa-
tients receiving liposomal irinotecan [6,7,9,20]. The sub-
stantial proportion (56%) of ITT patients meeting the PP
population analysis criteria, which excluded most of
those with rapid disease progression and/or tolerability
issues, highlights the efficacy and manageable toxicity of
nal-IRIþ5-FU/LV in this fragile patient population. The
nal-IRIþ5-FU/LV toxicity profile seen in NAPOLI-1 [6]
and the present PP analysis, and the lack of treatment-
associated neurotoxicity with this regimen, may make it
more suitable for use after first-line gemcitabine plus nab-
paclitaxel (a regimen associated with neurotoxicity [4])
than oxaliplatin-containing regimens, which are also
known to be associated with neurotoxicity [21,22].
5. Conclusions
This analysis improves our understanding of the efficacy
and safety of the nal-IRIþ5-FU/LV regimen in patients
with metastatic pancreatic cancer that progressed after
gemcitabine-based therapy. The significant survival in-
crease seen in PP patients who were treated with nal-
IRIþ5-FU/LV does not appear to be connected to
particular patient baseline characteristics compared with
the 5-FU/LV control group. The present data suggest that
nal-IRIþ5-FU/LV, used after failure of prior gemcitabine-
based therapy, increases survival vs 5-FU/LV alone in
metastatic pancreatic cancer patients of different thera-
peutic backgrounds and will help inform treatment de-
cisions considering typically heterogenous prior therapy
and varying degrees of AE-related treatment dose and
schedule modification.
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